A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
|Articles|May 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 5
- Volume 16
- Issue 5
AVEO and Schering-Plough to Develop Anti-HGF Antibody
AVEO and Schering-Plough to Develop Anti-HGF Antibody
Advertisement
CAMBRIDGE, Massachusetts—AVEO Pharmaceuticals, Inc. has entered into an exclusive worldwide agreement with Schering-Plough Corporation to develop and commercialize AV-299, a highly potent antagonist of hepatocyte growth factor/scatter factor (HGF/SF). The antibody has shown excellent efficacy in preclinical models of human cancer and is expected to enter clinical trials in early 2008, the companies announced in a press release.
Articles in this issue
over 19 years ago
Escalating Drug Costs Could Provoke Consumer Backlashover 19 years ago
Large Study Casts Doubt on Value of CADover 19 years ago
Cetuximab Does Not Increase Mucositis in H&N Cancerover 19 years ago
2004 Update Shows Continued Lower Breast Ca Incidenceover 19 years ago
Reclast Single-Dose Infusion Approved for Paget's Diseaseover 19 years ago
Fragmin Approved for VTE in Cancer Ptsover 19 years ago
New Phase III Trial of Genasense in Advanced Melanoma Plannedover 19 years ago
Cervical Cancer Vaccines Show Sustained Protectionover 19 years ago
The 'New' Medicare: Passive Payer No More; PQRI Is First StepAdvertisement
Related to this article
Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment selection.
T-DXd and Dato-DXd are now approved treatments in Japan for patients with breast cancer.
Data from the phase 3 EMBER-3 trial support the full approval of imlunestrant plus abemaciclib in this breast cancer population.
!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
The European Medicines Agency’s CHMP recommended approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer based on the ROSELLA trial.
Posters highlighted sex-based differences in aggressive B-cell NHL, third-line therapies in aggressive BCL, and real-world safety with CD20/CD3 bispecifics.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
2
Screening for CHIP Mutations to Guide CAR T Cell Candidacy in Lymphoma
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Daraxonrasib Receives FDA Breakthrough Therapy Status in 1L Metastatic PDAC
5